ENOV (Enovis) ROCE %: 1.21% (As of Mar. 2026)


ENOV Enovis Corp ENOV
61 GF Score
Price $21.38
GF Value $49.60
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Enovis ROCE %?

Enovis ENOV +1.09% 61 ROCE % is 1.21% as of Mar. 2026. GuruFocus rates ENOV with a GF Score™ of 61/100 and a GF Value™ of $49.60 (Possible Value Trap). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Enovis's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.21%.

Enovis  (NYSE:ENOV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Enovis ROCE % Related Terms

Enovis ROCE % Historical Data

* Premium members only.

The historical data trend for Enovis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enovis ROCE % Chart

Enovis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.32 0.39 -1.21 -18.39 -30.29

Enovis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.49 -1.48 -53.71 -56.61 1.21
ENOV
61GF Score
Enovis Corp ENOV
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enovis ROCE % Calculation

Enovis's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-1124.595/( ( (4718.777 - 528.998) + (3834.737 - 598.474) )/ 2 )
=-1124.595/( (4189.779+3236.263)/ 2 )
=-1124.595/3713.021
=-30.29 %

Enovis's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=39.212/( ( (3834.737 - 598.474) + (3832.256 - 608.665) )/ 2 )
=39.212/( ( 3236.263 + 3223.591 )/ 2 )
=39.212/3229.927
=1.21 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 1.21% mean?
Enovis (ENOV) has a ROCE % of 1.21% as of Mar. 2026.
Is Enovis' ROCE % too high?
Enovis' current ROCE % is 1.21%. The Medical Devices & Instruments industry median ROCE % is 2.23. Enovis' value of 1.21% is 45.7% below this industry median. Overall, Enovis has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enovis' ROCE % compare to IART and AHCO?
Enovis' ROCE % of 1.21% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Enovis' value of 1.21% is 45.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enovis's current ROCE % of 1.21% is 45.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enovis's current ROCE % is 1.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Based on GuruFocus' analysis, Enovis (ENOV) is currently considered Possible Value Trap. The stock's GF Value™ is $49.60, compared to a current price of $21.38 — trading 56.9% below its estimated fair value. The current ROCE % is 1.21% and 45.7% below the Medical Devices & Instruments industry median of 2.23. Enovis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Enovis (ENOV), the current ROCE % is 1.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enovis (ENOV) Overvalued in 2026?

Based on GuruFocus' analysis, Enovis stock appears to be undervalued. The current stock price of $21.38 is trading 56.9% below its estimated GF Value™ of $49.60. GuruFocus considers Enovis to be Possible Value Trap.

Key valuation signals for ENOV:

  • ROCE %: 1.21%
  • GF Value™: $49.60 vs. price of $21.38 (56.9% below fair value)
  • GF Score™: 61/100 with 6 warning signs
  • Industry Position: 45.7% below the Medical Devices & Instruments median

No single metric tells the full story. See the ENOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enovis Business Description

Address 2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
61GF Score

Get the complete analysis for ENOV

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.38
Price
$49.60
GF Value